OptionsHouse

Options Trading News

April 5, 2011  Tue 7:33 AM CT

CBST: SEE CHART GET CHAIN FIND STRATEGIES
Deal to Help Cubist Grow Business

CBSTThe drug maker settled a patent dispute with Teva Pharmaceutical Industries over its Cubicin antibiotic. The agreement delays TEVA's production of the drug as a generic by six months and will make it easier for Cubist to market the drug, its only product. CBST is up 15 percent in the premarket.


SemiLEDs Reports Surprise Loss

The maker of light-emitting diodes reported a loss of $0.03, missing the $0.08 profit forecast. Revenue and guidance also missed the mark, and LEDS is down 23 percent before the bell.


Questcor Sees Revenue Ahead of Consensus

The pharmaceuticals company said paid prescriptions for its Acthar Gel to treat multiple sclerosis more than doubled. The company estimated it had first-quarter sale of $48.6 million, while analysts had expected $33.60 million. QCOR climbs 14 percent before the bell.


(Chart courtesy of tradeMONSTER)
Share this article with your friends


OptionsHouse

TRADING WEEKLY OPTIONS

The fastest money in the market
View full report »

Premium Services

Upcoming Webinar:

Using Options For Income

http://bit.ly/1nY1OKA

Jon Najarian and Adam Mesh of Options Wealth Machine discuss a detailed strategy utilizing credit spreads to generate income, and how any level of trader can use this simple trading technique.

Education & Strategy

Sweet Spot Exceptions

As discussed last week, when using the Stock Replacement Strategy to replace a stock position to trade direction, we want to use an option that has very similar characteristics to the stock. We talked about using the deep in-the-money, 80 to 85 delta option that is similar in the Greeks and has relatively little extrinsic value which tends to work against us in stock directional trading.

View more education articles »